Johnson & Johnson Stock - Saturday business model review

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 13:07 UTC. Details in the imprint.

Johnson & Johnson (US4781601046) has no fresh live-verified corporate hook in the provided search results, so this Saturday article uses the business-model focus from the weekday module. The available market data still show the stock trading around $228.39 in New York, with a market cap near $549.78 billion.

What the market data show

TradingKey lists Johnson & Johnson at $228.39, with the quote shown after the June 18 close and delayed by 15 minutes. The same page puts market capitalization at $549.78 billion and shows a trailing P/E of 26.14.

Saturday business focus

For a long-term desk view, Johnson & Johnson still stands out for its split between pharmaceuticals and medtech. That mix gives the company multiple revenue engines, even when one segment cools.

The stock also sits inside a large-cap defensive profile. That matters on quiet weekends, when investors often compare healthcare names on durability rather than short-term momentum.

What the company sells

Johnson & Johnson’s portfolio includes prescription medicines, medical devices, and consumer health products. A representative product line is Stelara in immunology, alongside device franchises in orthopedics and surgery.

Where the stock trades today

The shares of Johnson & Johnson (US4781601046) trade on the NYSE at $228.39 as of 06/18/2026, 16:00 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.